Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)

Genitourinary Cancer

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients

Eur Urol

Armstrong AJ, Petrylak DP, Shore ND, Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Croitoru R, Wu R, Kalac M, Tang Y, Stenzl A, Azad AA

doi: 10.1016/j.eururo.2025.12.021

Genitourinary Cancer

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial

Eur Urol

Saad F, Shore N, Vjaters E, Olmos D, Littleton N, Testa I, Mo M, Verholen F, Srinivasan S, Haresh KP

doi: 10.1016/j.eururo.2026.07.026

Genitourinary Cancer

Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis

Prostate

Garcia de Herreros M, Rodrigo C, Ferrer-Mileo L, Fernández-Mañas L, Mases J, Diaz N, Vilaseca A, Altamirano M, Gibanel R, Ribal MJ, Jimenez N, Reig O, Figols M, Climent MÁ, Font A, Mellado B

doi: 10.1002/pros.70174

Genitourinary Cancer

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

Prostate Cancer Prostatic Dis

Büttner T, Rizzo M, Bernal Vaca L, Molina-Cerrillo J, Alonso-Gordoa T, Juárez A, Buchler T, Seront E, Kucharz J, Gandur Quiroga MN, Bourlon MT, Bögemann M, Kopecky J, Rescigno P, Fiala O, Rodriguez-Vida A, Myint ZW, Ürün Y, Scagliarini S, Poprach A, Matthews D, Li H, Rizzo A, Mosca A, Lenci E, Melichar B, Wenzel M, Mandell P, Massari F, Antonarakis ES, Santoni M

doi: 10.1038/s41391-025-01067-3

Genitourinary Cancer

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial

Eur J Cancer

Fizazi K, Smith MR, Hussain M, Saad F, Sternberg CN, David Crawford E, Aragon-Ching JB, Schostak M, Tutrone R, Morgans AK, Sentana-Lledo D, Joensuu H, Mohamed AF, Littleton N, Srinivasan S, Buttkewitz Y, Li R, Kuss I, Tombal B

doi: 10.1016/j.ejca.2026.116888

Genitourinary Cancer

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial

Lancet Oncol

Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F

doi: 10.1016/S1470-2045(26)00014-8

Genitourinary Cancer

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study

Ann Oncol

Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, Kwiatkowski M, Alvarez-Fernandez C, Jiang S, Sotelo M, Parslow D, Oliveira N, Kwon TG, Ye D, Boudewijns S, Danchaivijitr P, Rooney C, Gresty C, Yeste-Velasco M, Logan J, George DJ, CAPItello-281 Study Group

doi: 10.1016/j.annonc.2025.10.004

SPECIAL REPORT

Genitourinary Cancer

Sustained OS Benefit with Enzalutamide Plus ADT in mHSPC Including Patients with Cardiometabolic Comorbidities

Genitourinary Cancer

Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study

Urol Oncol

Rinderknecht E, Bielstein G, Cathomas R, Schlack K, Bastian JLD, Darr C, Unland-Gies D, Kappler P, Paffenholz P, Richter J, Müller M, Seitz AK, Steinestel J, Heidegger I, Burger M, Breyer J, Schnabel MJ

doi: 10.1016/j.urolonc.2026.111028

Related content

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial

Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study

Sustained OS Benefit with Enzalutamide Plus ADT in mHSPC Including Patients with Cardiometabolic Comorbidities

Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study